Risk adjusted net present value: What is the current valuation of Pharma Mar’s Ecubectedin?
Pharmaceutical Technology
JUNE 6, 2023
Ecubectedin is a small molecule commercialized by Pharma Mar, with a leading Phase II program in Hormone Sensitive Breast Cancer. Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). Buy the model here.
Let's personalize your content